Swiss Life Asset Management Ltd
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1637689
Zurich, V8
Position in PTGX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$417,139
+$89,978 QoQ
Shares Held
3,403
+9.6% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#225
of 341 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Swiss Life Asset Management Ltd holds $122,705,584 across 67 Biotechnology names. PTGX ranks #29 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
91,614 | $45,507,422 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
28,220 | $17,596,298 | |
| 3 | INCY |
Incyte Corp
|
104,901 | $11,891,577 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
29,327 | $8,828,306 | |
| 5 | RPRX |
Royalty Pharma plc
|
136,283 | $7,641,386 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
17,736 | $3,321,598 | |
| 7 | INSM |
INSMED Inc
|
27,552 | $2,937,594 | |
| 8 | MRNA |
Moderna, Inc.
|
25,088 | $1,756,912 |
All Filings in PTGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $417,139 | 3,403 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $327,161 | 3,104 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $212,323 | 2,431 | Shares | Sole | 2026-02-04 | |
| No filing history on record for this holder in this stock. | ||||||